Zachary L. Robbe

Zachary L. Robbe

Auto-generated profile, based on publicly available information

Zachary L. Robbe

Department of Immunology, Tufts University, Boston, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
CWCaralynn M. Wilczewski
Caralynn M. Wilczewski
AHAustin J. Hepperla
Austin J. Hepperla
TSTakashi Shimbo
Takashi Shimbo
LWLauren Wasson
Lauren Wasson
ZRZachary L. Robbe
Zachary L. Robbe
Frank ConlonFrank Conlon
Frank Conlon
Significance: Birth defects are the leading cause of infant mortality in the United States and Europe, with cardiac defects being the most prevalent. Here we define the requirement and mechanism of action of CHD4, the catalytic core component of the nucleosome remodeling and deacetylase (NuRD) complex, in embryonic heart development. CHD4 is essential from fly to human and mutations in CHD4 are causative to congenital heart disease, including atrial and ventricular septal defects. By generating a cardiac conditional null allele of CHD4, temporal transcriptional profiling, and systems-level analysis of CHD4 target genes and in utero echocardiography, we define molecular, biochemical, anatomical, and physiological mechanisms for CHD4 and the NuRD complex in repressing inappropriate expression of the skeletal and smooth muscle programs in the developing heart.

17 July 2024 in Nature Cardiovascular Research
Verified
Journal Article
Closed access
PDF file
ABAbraham L. Bayer
Abraham L. Bayer
MZMaria A. Zambrano
Maria A. Zambrano
SSSasha Smolgovsky
Sasha Smolgovsky
ZRZachary L. Robbe
Zachary L. Robbe
AAAbul Ariza
Abul Ariza
PAPilar Alcaide
Pilar Alcaide

1 January 2021 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
WSWei Shi
Wei Shi
XSXinlei Sheng
Xinlei Sheng
KDKerry M. Dorr
Kerry M. Dorr
JHJosiah E. Hutton
Josiah E. Hutton
HDHaley A. Davies
Haley A. Davies
FCFrank Conlon
Frank Conlon
Sex disparities in cardiac homeostasis and heart disease are well documented with male-female differences attributed to actions of sex specific hormones. However, recent studies implied sex chromosomes might act outside of the gonads to function in non-hormonal manner. How these two pathways contribute to cardiac sex differences remains unknown. Here, we performed both transcriptional and proteomics profiling to define the molecular differences between male and female mouse hearts. We demonstrate that, contrary to current dogma, cardiac sex disparities are controlled not solely by sex hormones, but also through a sex chromosome mechanism. Using Turner syndrome (XO) and Klinefelter (XXY) mouse models, we find that the sex chromosome pathway is established by X-linked gene dosage. We also show that cardiac sex dipartites occur at the earliest stages of heart formation, a period before gonad formation. These studies provide new insights and resources for studying sex-biased cardiac disease states.

28 October 2026 in Circulation Research
Verified
Journal Article
Closed access
RERamona Emig
Ramona Emig
ZRZachary Robbe
Zachary Robbe
CKCelina Kley
Celina Kley
SSSasha Smolgovsky
Sasha Smolgovsky
ABAbraham L Bayer
Abraham L Bayer
PAPilar Alcaide
Pilar Alcaide
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a major clinical challenge characterized by diastolic dysfunction. Left ventricular stiffening and inflammation are hallmarks of HFpEF, yet the contribution of ECM (extracellular matrix) stiffness and the immune-stromal mechanisms driving ECM stiffening in cardiometabolic HFpEF remain poorly understood. METHODS: We used the murine 2-hit model of cardiometabolic HFpEF, in which the combination of high-fat diet and hypertension induced by L-nitro-arginine-methyl ester causes diastolic dysfunction. We evaluated diastolic function by echocardiography and ECM mechanics by uniaxial tensile testing of decellularized cardiac tissue. Functional in vivo studies included genetic depletion of T cells, IFNγ (interferon-γ) knockout mice, and pharmacological lysyl oxidase inhibition. We combined cocultures of CD4 + T cells and cardiac fibroblasts with mechanical testing of cardiac ECM and molecular biology to elucidate cellular and molecular mechanisms. RESULTS: Left ventricular ECM stiffness strongly correlated with impaired diastolic function in experimental cardiometabolic HFpEF. Cardiac CD4 + T-cell infiltration was required for ECM stiffening and upregulation of lysyl oxidase enzymes in cardiac fibroblast. We discovered that CD4 + T-cell–derived IFNγ was required to induce LOXL3 in cardiac fibroblast, which increased ECM stiffness in vitro. Mechanistically, we demonstrate that a signaling axis involving IFNγ, PI3K (phosphoinositide 3-kinase), AKT, and HIF1α (hypoxia-inducible factor-1α) drives LOXL3 expression and subsequent collagen crosslinking. Genetic or pharmacological disruption of this IFNγ-HIF1α-LOXL3 axis attenuated adverse ECM remodeling and improved diastolic function. CONCLUSIONS: CD4 + T cells promote pathological ECM stiffening in cardiometabolic HFpEF through IFNγ-mediated, cardiac fibroblast LOXL3-dependent ECM crosslinking. Targeting this immune-stromal pathway may offer a novel therapeutic strategy for HFpEF.